HIV drugs by manufacturer

The TAG/i-Base Pipeline Report (July 2010) contains a detailed review of drugs in development for HIV, TB, hepatitis B, hepatitis C, vaccine research and basic science.

NOTE: The information below was produced in 2009.

Download as a Word Document [120 Kb]

Common Name Generic name/abbreviations Trade Name Class
GlaxoSmithKline (GSK)
AZT, ZDV zidovudine Retrovir NRTI
3TC lamuvidine Epvir NRTI
AZT + 3TC zidovudine+lamuvidine Combivir NRTI
ABC abacavir Ziagen NRTI
AZT+3TC+abacavir zidovudine+lamivudine+abacavir Trizivir NRTI
abacavir + 3TC abacavir+lamuvidine Kivexa NRTI
FPV fosamprenavir Telzvir PI
Pipeline Drugs
IDX899 NNRTI (Ph2)
GSK364735 INI (Ph1)
Bristol-Myers Squibb (BMS)
ddI didanosine Videx NRTI
d4T stavudine Zerit NRTI
EFV efavirenz Sustiva (EU) NNRTI
ATV atazanavir Reyataz PI
Atripla (with Gilead) efavirenz+FTC+tenofovir Atripla NNRTI+2NRTIs
Gilead Sciences
TDF tenofovir Viread NRTI
FTC emtricitabine Emtriva NRTI
Tenofovir+ FTC emtricitabine+tenofovir Truvada NRTI
Atripla (with BMS) efavirenz+FTC+tenofovir Atriprila NNRTI+2NRTIs
Pipeline Drugs
elvitegravir INI (Phase 3)
ETR etravirine Intelence NNRTI
DRV darunivir Prezista PI
Pipeline Drugs
TMC278 rilpvirine NNRTI (Ph 3)
RTV ritonavir Norvir PI
LPV lopinavir+ritonavir Kaletra (Aluvia) PI
DLV delavirdine Rescriptor NNRTI
NFV nelfinavir Viracept PI
MVC maraviroc Celsentri (Selzentry) EI
Pipeline Drugs
UK 543,061 NNRTI (Ph 1)
Common Name Generic Name Trade Name Class
NVP nevirapine Viramune NNRTI
TPV tipranavir Aptivus PI
Pipeline Drugs
BILR 355 NNRTI (Phase 2)
SQV saquinavir Invirase PI
T-20 enfuvirtide Fuzeon FI
IDV indinavir Crixivan PI
RGV raltegravir Isentress INI
Pipeline Drugs
Vicriviroc VCV EI (CCR5) Ph 3


Hepatatis C

Drugs that are used in combination:

Schering Plough:

  • pegylated interferon: (PegIFN) given by injection : There are two types of PEG interferon (Aalpha-2a, trade name pagasys) and Alpha-2b, trade name Peglntron or ViraferonPeg


  • ribavirin: RBV, given orally

Pipeline Drugs/Clinical trials: information can be found at:

TB Drugs:

1st line drugs: Generic drugs

  • ethambutol (EMB or E)
  • isoniazid (INH or H)
  • pyrazinamide (PZA or Z)
  • rifampicin (RMP or R)
  • streptomycin (STM or S)

2nd line drugs: (SLDs)

There are six classes of SLDs used for the treatment of TB. A drug may be classed as second-line instead of first-line for one of two possible reasons: it may be less effective than the first-line drugs (e.g., p-aminosalicylic acid); or, it may have toxic side-effects (e.g., cycloserine); or it may be unavailable in many developing countries (e.g., fluoroquinolones):

  • aminoglycosides: e.g., amikacin (AMK), kanamycin (KM)
  • polypeptides: e.g., capreomycin, viomycin, enviomycin
  • fluoroquinolones: e.g., ciprofloxacin (CIP), levofloxacin, moxifloxacin (MXF)
  • thioamides: e.g. ethionamide, prothionamide
  • cycloserine (the only antibiotic in its class)
  • p-aminosalicylic acid (PAS or P)

Other drugs that may be useful, but are not on the World Health Organisation (WHO) list of SLDs:

These drugs may be considered “third-line drugs” and are either because they are not very effective (e.g., clarithromycin) or because their efficacy has not been proven (e.g., linezolid, R207910). Rifabutin is effective, but is not included on the WHO list because for most developing countries, it is impractically expensive.

  • rifabutin
  • macrolides: e.g., clarithromycin (CLR)
  • linezolid (LZD)
  • thioacetazone (T)
  • thioridazine
  • arginine
  • vitamin D
  • R207910

Pipeline Drugs/Clinical trials: information can be found at:

Published: December 16, 2010
Last edited: January 7, 2011